-

Aptatek BioSciences, Inc. Announces Bridge Financing to Support Advancement of the PheCheck Aptamer-based In-home Monitoring Platform

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a pioneer in developing innovative in-home monitoring solutions for patients managing chronic diseases, today announced it has received bridge financing from Canterbury Scientific, Ltd, a current strategic investor. This latest funding tranche follows the successful advancement of Aptatek’s PheCheck™ platform, an FDA breakthrough diagnostic device designed for at-home monitoring of phenylalanine levels in patients with phenylketonuria (PKU).

Transforming chronic disease management through home monitoring solutions

Share

The new financing supports Aptatek’s ongoing clinical development and accelerates its path toward commercialization of its DNA aptamer-based home monitor for PKU, a genetic metabolic disorder, requiring diligent monitoring of phenylalanine levels to prevent serious health complications. As with diabetes management, maintaining optimal phenylalanine levels through diet and medication is essential for patient health and quality of life.

“This further funding from Canterbury Scientific strengthens our ability to bring our groundbreaking monitoring solution to PKU patients,” stated Dr. Michael Boyce-Jacino, CEO of Aptatek. “We deeply value Canterbury’s continued confidence and strategic partnership as we move closer to commercialization.”

Clive Seymour, CEO of Canterbury Scientific, a leading global OEM supplier of IVD controls, added, “Aptatek is at the forefront of revolutionizing home health management. We are excited to support the commercialization of their innovative and patient-centric approach to chronic disease monitoring, offering patients greater control over their health outcomes and daily lives.”

Founded as a spin-out from Columbia University, Aptatek BioSciences, Inc. leverages advanced aptamer technology to create simple, reliable, quantitative, point-of-care diagnostics that empower patients with chronic conditions to manage their health effectively from home.

Contacts

Michael Boyce-Jacino, CEO, Aptatek BioSciences, Inc.
info@aptatek.com, (609) 474-0716

Aptatek BioSciences, Inc.


Release Versions

Contacts

Michael Boyce-Jacino, CEO, Aptatek BioSciences, Inc.
info@aptatek.com, (609) 474-0716

More News From Aptatek BioSciences, Inc.

Aptatek BioSciences, Inc. Closes Funding Tranche Based on Successful Clinical Evaluation of Its PheCheckTM Aptamer-Based In-Home Monitoring Platform

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a developer of in-home health monitoring solutions for patients with chronic disease, announced the completion of a funding round led by Canterbury Scientific, LDT, and the National PKU Alliance (NPKUA). The funding, based on the successful initial clinical evaluation of Aptatek’s first product, will be used to complete clinical studies of its groundbreaking in-home monitoring platform for phenylketonuria (PKU). This chronic, rare inh...

Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences, Inc., a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director. He joins Ali Tinazli, PhD, CEO of Lifespin Health, as part of the growing team of highly experienced industry professionals on Aptatek’s board of directors. Lee has more than 30 years of pharmaceutical, biotech, diagnostics, device, and venture capital experience. He has h...

Aptatek BioSciences, Inc. Completes $4 Million Seed Funding Led by IP Group, Inc. to Develop Advanced In-Home Monitoring of Chronic Disease

PRINCETON, N.J.--(BUSINESS WIRE)--Aptatek BioSciences seed financing led by IP Group and supporting development of home monitoring for chronic disease....
Back to Newsroom